Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Six Month Double-Blind, Placebo-Controlled Phase 2 Clinical Trial to Determine the Safety and Efficacy of Idebenone Administered to Patients With Friedreich's Ataxia
Brief Summary: This study will determine whether a drug called idebenone is safe and effective in reducing the level of oxidants that are believed to damage the nervous system and hearts in patients with Friedreich's ataxia. Friedreich's ataxia is caused by an abnormality in the gene that makes a protein called frataxin, which is necessary for the proper functioning of energy-producing parts of cells called mitrochondria. In Friedreich's ataxia, the mitochondria become overloaded with iron, and high levels of harmful compounds called oxidants are formed. These oxidants are believed to damage the cells of the nervous system and hearts of people with Friedreich's ataxia. Idebenone is a man-made drug similar to a naturally occurring compound known as Coenzyme Q10. This study will test whether idebenone can alleviate some of the symptoms of Friedreich's ataxia and slow or halt the progression of the disease.

Patients with genetically confirmed Friedreich's ataxia who are between 9 and 18 years of age, weigh between 65 and 175 pounds and can walk 25 feet with or without an assistive device may be eligible for this study. Candidates are screened with blood tests and a review of their medical records.

Participants undergo the following tests and procedures:

* Medical interview and physical examination. Tests include blood and urine tests, an electrocardiogram, or EKG (recording of the electrical activity of the heart), echocardiogram (ultrasound test showing the pumping action of the heart, thickness of the heart walls, and any valve leakage), and a detailed neurological examination, including maneuvers such as copying a drawing and putting pegs in a board. Patients' parents are asked questions about how they feel their child's disease affects the child's quality of life.
* Magnetic resonance imaging (MRI) to examine the heart muscle and blood flow to the heart. MRI uses a magnetic field and radio waves to produce images of body tissues and organs. The patient lies on a table that is moved into the doughnut-shaped MRI scanner, wearing earplugs to muffle loud knocking and thumping sounds that occur during the scanning process. A catheter (plastic tube) is placed in a vein in the child's arm so that a chemical called gadolinium can be injected during the MRI study. Gadolinium brightens areas of the heart, improving the ability to see the heart and blood flow.
* Physical medicine and rehabilitation evaluations to test the child's physical functioning. These tests include gait evaluation, measurements of the ability to exert and maintain a constant force, assessment of visual-motor control and fine motor control, aerobic exercise endurance testing, and measurement of the ability of the child's heart and lungs to increase their effectiveness with exercise.
* Idebenone/placebo treatment. Patients are given a 6-month supply of either idebenone pills or placebo (pills that look like the study drug but have no active ingredient) to take three times a day. Patients are seen by their primary care physician after 1 and 3 months on the study medication for a brief physical examination. In addition, they have blood and urine tests once a month while on medication to check for any abnormalities.
* 6-month examination. After 6 months on the study drug, patients return to NIH to repeat all the tests listed above to determine the effects of idebenone treatment.


Options:
A: Intervention Type: PROCEDURE; Name: electronic diary; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Sertraline; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: voice acoustics; Assigned to Arm(s): N/A
B: Arm Label: Arm 1 - 900 mg/day Idebenone; Type: EXPERIMENTAL; Interventions: Drug: Idebenone | Arm Label: Arm 2 - up to 2250 mg/day Idebenone; Type: EXPERIMENTAL; Interventions: Drug: Idebenone | Arm Label: Arm 3 - Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Idebenone; Assigned to Arm(s): Arm 1 - 900 mg/day Idebenone | Intervention Type: DRUG; Name: Idebenone; Assigned to Arm(s): Arm 2 - up to 2250 mg/day Idebenone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm 3 - Placebo
C: Intervention Type: DRUG; Name: Idebenone; Assigned to Arm(s): N/A
D: Arm Label: Low Dose; Type: EXPERIMENTAL; Interventions: Drug: alpha-tocopherolquinone (A0001) | Arm Label: High Dose; Type: EXPERIMENTAL; Interventions: Drug: alpha-tocopherolquinone (A0001) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: alpha-tocopherolquinone (A0001); Assigned to Arm(s): Low Dose | Intervention Type: DRUG; Name: alpha-tocopherolquinone (A0001); Assigned to Arm(s): High Dose | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: C